Related references
Note: Only part of the references are listed.Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients
Meng He et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2019)
Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
Changhoon Yoo et al.
CANCERS (2019)
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
Quisette P. Janssen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma
Ayhan Ulusakarya et al.
MEDICINE (2019)
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review
Fabiana Napolitano et al.
CANCERS (2019)
Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery
Yuichi Nagakawa et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population
Xiang Li et al.
ONCOLOGIST (2019)
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study
Mustafa Suker et al.
JOURNAL OF SURGICAL ONCOLOGY (2018)
Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis
Alex Barenboim et al.
EJSO (2018)
Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer A single center experience
Jongchan Lee et al.
MEDICINE (2018)
Multi-disciplinary management of locally advanced pancreatic cancer with irreversible electroporation
Robert C. G. Martinii
JOURNAL OF SURGICAL ONCOLOGY (2017)
Pancreatic Adenocarcinoma, Version 2.2017
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
G. Lakatos et al.
PATHOLOGY & ONCOLOGY RESEARCH (2017)
Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary
Edward P. Balaban et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience
Muralidharan K. Chllamma et al.
BRITISH JOURNAL OF CANCER (2016)
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stacey M. Stein et al.
BRITISH JOURNAL OF CANCER (2016)
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
Mustafa Suker et al.
LANCET ONCOLOGY (2016)
Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma
Eric A. Mellon et al.
ACTA ONCOLOGICA (2015)
FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma
Eran Sadot et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Approach to Patients With Pancreatic Cancer Without Detectable Metastases
Gregory M. Heestand et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
Marlo Blazer et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
L. Marthey et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience
Sing Yu Moorcraft et al.
CLINICAL COLORECTAL CANCER (2014)
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: A single institution retrospective review
Florian Hohla et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
Sophie Gourgou-Bourgade et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer
Brian A. Boone et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity
Krishna S. Gunturu et al.
MEDICAL ONCOLOGY (2013)
FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience
Jason E. Faris et al.
ONCOLOGIST (2013)
Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
Hemchandra Mahaseth et al.
PANCREAS (2013)
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis
Qing Zhao et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2012)
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
Peter J. Hosein et al.
BMC CANCER (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma
Deyali Chatterjee et al.
CANCER (2012)
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Daniel Habermehl et al.
RADIATION ONCOLOGY (2012)
Quantifying the impact of between-study heterogeneity in multivariate meta-analyses
Dan Jackson et al.
STATISTICS IN MEDICINE (2012)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials
M. Mura Assifi et al.
SURGERY (2011)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
Mark P. Callery et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary
Milena Sant et al.
EUROPEAN JOURNAL OF CANCER (2009)
Pancreatic cancer: Incidence, treatment and survival trends-1175 cases in Calvados (France) from 1978 to 2002
A. -C. Lefebvre et al.
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE (2009)
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study
B. Chauffert et al.
ANNALS OF ONCOLOGY (2008)
Comparison of two methods to detect publication bias in meta-analysis
JL Peters et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
CH Crane et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Share Paper
